MJMonika Jurkowska

Monika Jurkowska

*This is an algorithmically generated author record based on publicly available information.

Monika Jurkowska has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 July 2015
      • Vol. 8  (7) , 8487-93

    Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.

    by Monika Jurkowska, Aleksandra Gos, Konrad Ptaszyński, Wanda Michej, Andrzej Tysarowski, Renata Zub, Janusz A Siedlecki, Piotr Rutkowski

    The study compares detection rates of oncogenic BRAF mutations in a homogenous group of 236 FFPE cutaneous melanoma lymph node metastases, collected in one cancer center. BRAF mutational status was verified by two independent in-house PCR/Sanger sequencing tests, and the Cobas® 4800 BRAF V600 Mutation Test. The best of two sequencing approaches returned results for 230/236 samples. In 140 (60.9%), the mutation in codon 600 of BRAF was found. 91.4% of all mutated cases (128 samples) represented p.V600E. Both Sanger-based tests gave reproducible results although they differed significantly in the percentage of amplifiable samples: 230/236 to 109/143. Cobas generated results in all 236 cases, mutations changing codon V600 were detected in 144 of them (61.0%), including 5 not amplifiable and 5 negative in the standard sequencing. However, 6 cases positive in sequencing turned out to be negative in Cobas. Both tests provided us with the same BRAF V600 mutational status in 219 out of 230 cases with valid results (95.2%). The total BRAF V600 mutation detection rate didn't differ significantly between the two methodological approaches (60.9% vs. 61.0%). Sequencing was a reproducible method of V600 mutation detection and more powerful to detect mutations other than p.V600E, while Cobas test proved to be less susceptible to the poor DNA quality or investigator's bias. The study underlined an important role of pathologists in quality assurance of molecular diagnostics.


    • 1 January 2005
      • Vol. 62  (12) , 1412-6

    [Genetic polymorphism and outcome in acute lymphoblastic leukaemia of childhood].

    by Monika Jurkowska, Iwona Malinowska, Jerzy Bal

    Current treatment strategies of leukaemia use risk factors existing at the time of diagnosis to establish risk-adapted therapy. This approach currently results in overall 95% rate of complete remission in paediatric acute lymphoblastic leukemia (ALL). However, as many as 30% of patients suffer from relapse and majority of children with ALL is profoundly affected by toxicity of anticancer drugs. In our study the probability of event free survival in children presenting with normal blast karyotype and treated according to BFM 90 protocol was 75%. This suggests the existence of factors independent from leukaemia genetic background, which influences the outcome of patients with ALL. This review is focused on genetic and functional polymorphism of enzymes that have or may have the influence on metabolism of drugs included in treatment protocol for ALL in children. Basic enzymes of anticancer drug metabolic pathways are described and frequency of their polymorphisms in Caucasian population is discussed.